NCT03932162

Brief Summary

This study does not involve any particular diagnosis. The goal of this research study is to explore the effects of artificial sunlight (ultraviolet B radiation; UVB) on the skin of young adults versus geriatric adults. Sunlight exerts many effects on the body. There is evidence that in response to ultraviolet B radiation (UVB), which are the burning rays of sunlight, young adult skin responds differently than geriatric skin. In fact, researchers feel that this difference in how the skin reacts to UVB is why skin cancers are found in older skin. Researchers believe that a major difference between young adult and geriatric skin is that young skin has a lot of a protein called insulin-like growth factor-1 (IGF-1), whereas geriatric skin has very little. The current study will test how young adult versus geriatric skin responds to UVB, and if geriatric skin treated with an injection of small amount of IGF-1 drug will then act like young skin.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
24

participants targeted

Target at P25-P50 for early_phase_1

Timeline
Completed

Started Sep 2019

Longer than P75 for early_phase_1

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 26, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 30, 2019

Completed
4 months until next milestone

Study Start

First participant enrolled

September 6, 2019

Completed
6.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

February 6, 2025

Status Verified

February 1, 2025

Enrollment Period

6.2 years

First QC Date

April 26, 2019

Last Update Submit

February 5, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in expression genes involved in protecting skin cells from UVB damage in younger skin and geriatric skin injected with IGF-1 from baseline

    Expression genes involved in protecting skin cells from UVB damage, including p21, xeroderma pigmentosum (XPC), and polymerase eta, will be higher following UVB exposure in younger skin and geriatric skin injected with IGF-1 than in geriatric skin injected with saline as a control.

    2 Days

Study Arms (2)

Young Adult

PLACEBO COMPARATOR

One small area of skin will undergo treatment with a small amount of UVB.

Other: No Insulin-Lie Growth Factor 1

Geriatric Adult

ACTIVE COMPARATOR

Four small areas will undergo injection of a small amount of IGF-1 drug and two will undergo injections with saline. Then the injected areas will be treated with a small amount of UVB.

Drug: Insulin-Like Growth Factor 1

Interventions

Growth factor protein

Geriatric Adult

No Insulin-Like Growth Factor 1 will be given.

Young Adult

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male/Female
  • White skin (Fitzpatrick types I and II)
  • Age 21-30 or 65 and older
  • Able to comprehend procedures/risks

You may not qualify if:

  • Known photosensitivity
  • Currently on photosensitizing medications
  • Diabetes Mellitus
  • History of abnormal scarring
  • History of skin infections
  • Known allergy to lidocaine local anesthetic
  • Pregnancy or nursing
  • Other serious health issues

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wright State Physicians

Fairborn, Ohio, 45324, United States

RECRUITING

MeSH Terms

Interventions

Insulin-Like Growth Factor I

Intervention Hierarchy (Ancestors)

SomatomedinsInsulin-Like PeptidesIntercellular Signaling Peptides and ProteinsPeptidesAmino Acids, Peptides, and ProteinsBlood ProteinsProteinsBiological Factors

Study Officials

  • Jeffrey B Travers, MD, PhD

    Wright State University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Manager, Clinical Research Operations

CONTACT

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 26, 2019

First Posted

April 30, 2019

Study Start

September 6, 2019

Primary Completion

December 1, 2025

Study Completion

December 1, 2025

Last Updated

February 6, 2025

Record last verified: 2025-02

Locations